Don Hertzog

Don Hertzog joined Inception as Head of Chemistry in 2022 after serving as a Senior Research Fellow at Enveda Therapeutics and leading the chemistry departments at both Ribometrix, Inc. and HemoShear Therapeutics, as well as the Early Lead Discovery team at Abide Therapeutics. Prior to moving into biotech, Don held a variety of leadership positions at both Bayer and GlaxoSmithKline (GSK), during which time Don and his teams identified multiple clinical development compounds. Don brings expertise in all aspects of drug discovery from early lead identification through clinical candidate selection. Don obtained PhD with Albert Padwa at Emory University and then completed an NIH-sponsored postdoctoral fellowship in medicinal chemistry with Dale Boger at the Scripps Research Institute.